Stock comparison
BioCryst Pharmaceuticals
BCRX
Market cap
$2.14B
Sector
Healthcare
Overall winner
IDEXX Laboratories
BCRX 0–7 IDXX
IDEXX Laboratories
IDXX
Market cap
$44.34B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
BCRXvsIDXX
40D
75B
24F
81A
40D
76B
60C
71B
4F
83C
35D
87A
41D
84A
Side-by-side metrics
| Metric | BCRX | IDXX |
|---|---|---|
| Market cap | $2.14B | $44.34B |
| P/E (TTM) | - | 40.3x |
| EV/EBIT | 7.6x | 32.6x |
| ROIC (TTM) | -121.96% | 40.66% |
| Gross margin | 18.89% | 62.05% |
| Net margin | -51.71% | 24.63% |
| Revenue CAGR 5y | 53.6% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BCRX leads on
- Debt / Equity-vs 0.7x+145%
- P/E (TTM)-vs 40.3x+112%
- Revenue CAGR 5y53.6%vs 7.56%+86%
- EV/EBIT7.6xvs 32.6x+77%
IDXX leads on
- Net margin24.63%vs -51.71%+148%
- ROIC (TTM)40.66%vs -121.96%+133%
- Market cap$44.34Bvs $2.14B+95%
- Gross margin62.05%vs 18.89%+70%
More like BCRX
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.